Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer

医学 乳腺癌 肿瘤科 内科学 置信区间 临床终点 人口 内分泌系统 癌症 临床试验 激素 环境卫生
作者
Ulrike Nitz,Oleg Gluz,Sherko Kümmel,Matthias Christgen,Michael Braun,Bahriye Aktas,Kerstin Lüdtke-Heckenkamp,Helmut Forstbauer,Eva‐Maria Grischke,Claudia Schumacher,Maren Darsow,Katja Krauss,Benno Nuding,Marc Thill,Jochem Potenberg,Christoph Uleer,Mathias Warm,Hans Holger Fischer,Wolfram Malter,Michael Hauptmann
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (23): 2557-2567 被引量:89
标识
DOI:10.1200/jco.21.02759
摘要

To our knowledge, WSG-ADAPT-HR+/HER2- (ClinicalTrials.gov identifier: NCT01779206; n = 5,625 registered) is the first trial combining the 21-gene expression assay (recurrence score [RS]) and response to 3-week preoperative endocrine therapy (ET) to guide systemic therapy in early breast cancer.Baseline and postendocrine Ki67 (Ki67post) were evaluated centrally. In the endocrine trial, all patients received exclusively ET: patients with pathologic regional lymph node status (pN) 0-1 (ie, 0-3 involved lymph nodes) entered control arm if RS ≤ 11 and experimental arm if RS12-25 with ET response (Ki67post ≤ 10%). All other patients (including N0-1 RS12-25 without ET response) received dose-dense chemotherapy (CT) followed by ET in the CT trial. Primary end point of the endocrine trial was noninferiority of 5-year invasive disease-free survival (5y-iDFS) in experimental (v control) arm; secondary end points included distant DFS, overall survival, and translational research.Intention-to-treat population comprised 2,290 patients (n = 1,422 experimental v n = 868 control): 26.3% versus 34.6% premenopausal and 27.4% versus 24.0% pN1. One-sided 95% lower confidence limit of the 5y-iDFS difference was -3.3%, establishing prespecified noninferiority (P = .05). 5y-iDFS was 92.6% (95% CI, 90.8 to 94.0) in experimental versus 93.9% (95% CI, 91.8 to 95.4) in control arm; 5-year distant DFS was 95.6% versus 96.3%, and 5-year overall survival 97.3% versus 98.0%, respectively. Differences were similar in age and nodal subgroups. In N0-1 RS12-25, outcome of ET responders (ET alone) was comparable with that of ET nonresponders (CT) for age > 50 years and superior for age ≤ 50 years. ET response was more likely with aromatase inhibitors (mostly postmenopausal) than with tamoxifen (mostly premenopausal): 78.1% versus 41.1% (P < .001). ET response was 78.8% in RS0-11, 62.2% in RS12-25, and 32.7% in RS > 25 (n = 4,203, P < .001).WSG-ADAPT-HR+/HER2- demonstrates that guiding systemic treatment by both RS and ET response is feasible in clinical routine and spares CT in pre- and postmenopausal patients with ≤ 3 involved lymph nodes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Forestzoo应助yao chen采纳,获得10
刚刚
Ccc发布了新的文献求助10
刚刚
哈哈哈哈哈完成签到,获得积分10
刚刚
zumri完成签到,获得积分20
1秒前
小琰砸完成签到,获得积分10
1秒前
1秒前
ShaodongLIU发布了新的文献求助10
1秒前
李爱国应助万事如懿采纳,获得10
2秒前
3秒前
3秒前
3秒前
feihua发布了新的文献求助10
4秒前
冬青完成签到,获得积分20
4秒前
4秒前
4秒前
SciGPT应助Erik采纳,获得10
5秒前
方方完成签到,获得积分10
5秒前
5秒前
zhaxiao发布了新的文献求助10
6秒前
小马甲应助wjx采纳,获得10
6秒前
彪yu发布了新的文献求助10
7秒前
Okayoooooo发布了新的文献求助20
8秒前
Brian完成签到,获得积分10
8秒前
8秒前
紫紫发布了新的文献求助10
8秒前
minion发布了新的文献求助10
8秒前
9秒前
大模型应助高序采纳,获得10
9秒前
sln发布了新的文献求助10
9秒前
淡定映之发布了新的文献求助10
9秒前
酷波er应助朝天采纳,获得10
9秒前
认真的火发布了新的文献求助10
10秒前
赘婿应助科研通管家采纳,获得80
10秒前
10秒前
10秒前
11秒前
11秒前
11秒前
11秒前
11秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974856
求助须知:如何正确求助?哪些是违规求助? 3519400
关于积分的说明 11198085
捐赠科研通 3255563
什么是DOI,文献DOI怎么找? 1797860
邀请新用户注册赠送积分活动 877208
科研通“疑难数据库(出版商)”最低求助积分说明 806219